HIRSCHHORN MARK sold $127K of AMWL

HIRSCHHORN MARK (Chief Financial Officer) sold 10,751 shares of American Well Corp (AMWL) at $11.80 ($0.13M total) on 2026-09-01.

Original reporting
SEC EDGAR · HIRSCHHORN MARK
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMWL
Neutral
medium confidence
Mentioned
$AMWL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLNeutralLow
01

Why it matters

The CFO's sale is modest in dollar terms and unlikely to move the stock materially.

02

Market read

A routine insider sale with limited price impact.

03

What to watch

CFO may be diversifying holdings; no change in company fundamentals.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 disclosures provide the first public notice of insider transactions.

Company-level read

Ticker impact

$AMWLNeutralMedium confidence
Context

CFO Mark Hirschhorn sold 10,751 shares for $126,861.80, reducing his holdings to 228,188 shares.

Expected impact

Potential slight downward pressure, likely limited to low single‑digit basis points.

Evidence & confidence

The transaction is a routine Form 4 filing; amount is under $1 M, so market reaction is expected to be muted.

Market effects

None significant for the broader health‑tech sector.

No notable regional effect.

Limited to AMWL investors.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company outlook.

Key entities

  • Mark Hirschhorn

    Chief Financial Officer of American Well Corp.

  • American Well Corp

    Provider of telehealth services, ticker AMWL.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.